Investor Lists

Family offices backing Biotech

Updated 7 November 2026

Family offices we have observed in a biotech round in the last two years.

See all 23 →The top 23
23investors on the list+2 this week
153cheques in 12 months+11% against the market
$25Mmedian round they joined+213% against the market median
96%wrote a cheque in 12 months
52%have led a round

The Top 23

Ordered by cheques observed, never by anything anyone paid for

Deploying now (22)

  1. 1Hill House CapitalDeploying nowFamily office · Singapore248$60Mmedian roundSept 2026last seen
  2. 2Thrive CapitalDeploying nowFamily office240$50Mmedian roundOct 2026last seen
  3. 3Real VenturesDeploying nowFamily office · Brazil210$5Mmedian roundOct 2026last seen
  4. 4Vulcan CapitalDeploying nowFamily office · United States118$7Mmedian roundJul 2026last seen
  5. 5Declaration PartnersDeploying nowFamily office · United States90$25Mmedian roundOct 2026last seen
  6. 6Winklevoss CapitalDeploying nowFamily office · United States86$14Mmedian roundMay 2026last seen
  7. 7Elkstone Capital PartnersDeploying nowFamily office · Ireland57$4Mmedian roundSept 2026last seen
  8. 8EvolemDeploying nowFamily office · France49$4.3Mmedian roundSept 2026last seen
  9. 9Farvatn VentureDeploying nowFamily office · United States32$2.8Mmedian roundJun 2026last seen
  10. 10Emerson CollectiveDeploying nowFamily office · United States27$62Mmedian roundOct 2026last seen
  11. 11Euclidean CapitalDeploying nowFamily office · United States11$65Mmedian roundOct 2026last seen
  12. 12Kibo InvestDeploying nowFamily office · Singapore11$13Mmedian roundOct 2026last seen
  13. 13Jefferson Life SciencesDeploying nowFamily office5$65Mmedian roundOct 2026last seen
  14. 14Navus VenturesDeploying nowFamily office · Netherlands5$8.8Mmedian roundApr 2026last seen
  15. 15KorysDeploying nowFamily office · Belgium4$53Mmedian roundJun 2026last seen
  16. 16Domino VenturesDeploying nowFamily office · United States2$1.1Mmedian roundOct 2026last seen
  17. 17StandardDeploying nowFamily office · France2$283Mmedian roundOct 2026last seen
  18. 18Stephen IndustriesDeploying nowFamily office · Finland2$31Mmedian roundSept 2026last seen
  19. 19Pennant InvestorsquietFamily office · United States2$143Mmedian roundSept 2025last seen
  20. 20Lakeside CapitalDeploying nowFamily office · United States1$1.8Mmedian roundNov 2026last seen
  21. 21Lightfield EquityDeploying nowFamily office · Germany1-median roundNov 2026last seen
  22. 22Gold Mine Multi Family OfficeDeploying nowFamily office1-median roundMay 2026last seen
  23. 23Seattle based family officeDeploying nowFamily office1$52Mmedian roundMay 2026last seen

Reading for founders in health and biotech

More books for founders and investors on the Reading List.

As an Amazon Associate we earn from qualifying purchases.

Quick answers about family offices backing Biotech

Who are the most active family offices backing Biotech?

By cheques observed, the most active are Hill House Capital, Thrive Capital, Real Ventures, Vulcan Capital and Declaration Partners.

How many family offices backing Biotech are there?

23 are on record. 96% made an investment in the last 12 months and 52% have led a round.

Which stages do family offices backing Biotech back?

Of the rounds with a named stage in the last 12 months, mostly Series A (27%) and Seed (19%).

How big are the rounds family offices backing Biotech join?

The typical (median) round among the leading investors here is $25M.

Which sectors do family offices backing Biotech back most?

In the last 12 months, mostly AI, Biotech and Healthcare.

Which family offices backing Biotech lead the most rounds?

Thrive Capital (18 led), Hill House Capital (3 led) and Vulcan Capital (3 led).

Where are family offices backing Biotech based?

Among the most active, most are based in the United States (9), Singapore (2) and France (2).

What have family offices backing Biotech invested in recently?

Recent rounds include ArrayPatch (Seed, Nov 2026, with Lakeside Capital), Potential Sciences (Seed, Nov 2026, with Lightfield Equity) and Setara Biosciences (Series A, Oct 2026, with Euclidean Capital).

Built from the rounds we watched, refreshed every night. How we count · Report a correction